Prepared by Dr. Sofia Chen, FRM, Head of Quantitative Research | Reviewed by David Miller, Lead Editor | Report ID: IGEMINI-F3AC7D51-20260531 | Data as of 2026-05-31
Executive Summary: Our multi-factor model assigns care equity a Cautiously Constructive outlook for the next quarter. Key drivers include a P/E of 48.23x, 31.8% revenue expansion, and an RSI of 38 suggesting a neutral-bullish phase. We define critical support at $1233.9 and resistance at $1508.1.
Rating: Outperform | Target Price: $1658.91 | Next Earnings: Jun 21
Download Full PDF Report
Price action carved a Bull Flag, confirmed by a 1.44x volume spike on May 10, 2026. The support at $1233.9 was tested.
MACD printed a Bearish Divergence as the 50-day SMA turned positive 29 days ago.
Bollinger Bands contracted to the 15th percentile, signaling a breakout. A close above $1576.65 would be bullish.
Relative to Consumer Cyclical peers, care equity sits at the 56th percentile in valuation, offering a potential value opportunity.
EPS of $28.43 reveals above-sector earnings quality. DuPont analysis highlights margin expansion as the key ROE driver.
Free cash flow conversion remains robust at 93%, supporting the 3.84% dividend and buybacks.
Short float at 8.8% is below the sector average, reducing squeeze risk. Institutional ownership is 76%.
Dark pool prints show a 12%% surge in block trades, indicating institutional accumulation before Jun 21 earnings.
Beta of 0.84 suggests care equity is {beta_desc} volatile than the market, influencing hedging strategies.
| Metric | Value | Sector Avg |
|---|---|---|
| Last Price | $1371 | $1302.45 |
| Market Cap | $1.99B | $2.39B |
| P/E Ratio | 48.23x | 41x |
| EPS (TTM) | $28.43 | $25.59 |
| Dividend Yield | 3.84% | 2.7% |
| Revenue Growth | 31.8% | 19.1% |
| Target Price | $1658.91 | - |
| Beta | 0.84 | 1.00 |